Best Biotech Stocks To Follow Today – December 31st

Abivax, Danaher, and Cogent Biosciences are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that research, develop and commercialize biological technologies, drugs, diagnostics, and related health-care innovations. They are often characterized by heavy R&D spending, reliance on clinical trial outcomes and regulatory approvals, and therefore can be higher-risk but higher-reward than many other sectors. Many biotech firms are small-cap or pre-revenue and dependent on partnerships, patents and external financing for growth. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Abivax (ABVX)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Cogent Biosciences (COGT)

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.